The U.S. Food and Drug Administration (FDA) has approved DTX401, a gene therapy developed by Ultragenyx for the treatment of GSDIa. Find out more here:
FDA approves treatment for GSD1a in the U.S.
The U.S. Food and Drug Administration (FDA) has approved DTX401, a gene therapy developed by Ultragenyx for the treatment of GSDIa. Find out more here: